Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





New Breakthrough Test Detects and Predicts COVID-19 Severity

By LabMedica International staff writers
Posted on 16 Sep 2022

COVID19 is on pace to be the third-leading cause of death for the third straight year. More...

Since 2020, it has trailed only heart disease and cancer, significantly reducing life expectancy. One of the current clinical challenges in treating COVID is the inability to predict whether a person who tests positive will develop a mild, moderate or severe case. Now, a simple, efficient and quick genomic blood test could be a game-changer in identifying patients who may experience a severe course of COVID and to provide decision support for the type of medical treatments that may be helpful.

AMPEL BioSolutions (Charlottesville, VA, USA) has made a breakthrough in precision and personalized medicine that can detect and predict the severity of COVID-19 in patients while also determining the best treatment options for each specific case. AMPEL's new genomic test, known as CovGENE, can be administered by drawing a patient's blood to quickly ascertain whether a COVID-19 patient will have a mild, moderate, or severe outcome. After a patient tests positive, the CovGENE blood test will help determine the type of treatment and medicine needed in order to reduce the chances of hospitalization or a medical emergency. The company's new approach, through a simple blood test, will ultimately accelerate the means of providing effective treatments to the right people at the right time and potentially stem the serious illness caused by SARS-CoV-2 infection that can lead to lung damage or death.

CovGENE, has been validated by a longitudinal study. In a careful analysis of patients admitted to the intensive care unit, CovGENE demonstrated remarkable precision with a greater than 90% rate of accuracy. CovGENE is becoming available at a crucial time as variants emerge across the globe and as we head into fall and winter, where we’ve experienced major spikes the last two years. CovGENE also holds promise in predicting long COVID, an elusive diagnosis the medical community is still trying to fully understand.

"Now that this unique approach has been validated, we look forward to its rapid development as a precision medicine tool that can improve the outcome of patients with COVID-19 and reduce the number of hospitalizations, especially the most vulnerable," said r. Peter Lipsky, AMPEL Chief Medical Officer, CEO and co-founder.

Related Links:
AMPEL BioSolutions 


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Portable Electronic Pipette
Mini 96
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The patented biosensor measures enzymatic activity associated with inflammatory disease (Photo courtesy of Hawkeye Bio)

Non-Invasive and Radiation-Free Diagnostic Identifies Early-Stage Lung Cancer Across All Subtypes

Lung cancer remains the leading cause of cancer-related deaths, with nearly 125,000 deaths and 227,000 new cases estimated in the U.S. for 2025. Despite evidence showing that early detection significantly... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.